Battaglia, G.; Lazzarotto, D.; Tanasi, I.; Gurrieri, C.; Forlani, L.; Mauro, E.; Capraro, F.; Ciotti, G.; De Bellis, E.; Callegari, C.;
et al. New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers. J. Clin. Med. 2025, 14, 700.
https://doi.org/10.3390/jcm14030700
AMA Style
Battaglia G, Lazzarotto D, Tanasi I, Gurrieri C, Forlani L, Mauro E, Capraro F, Ciotti G, De Bellis E, Callegari C,
et al. New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers. Journal of Clinical Medicine. 2025; 14(3):700.
https://doi.org/10.3390/jcm14030700
Chicago/Turabian Style
Battaglia, Giulia, Davide Lazzarotto, Ilaria Tanasi, Carmela Gurrieri, Laura Forlani, Endri Mauro, Francesca Capraro, Giulia Ciotti, Eleonora De Bellis, Chiara Callegari,
and et al. 2025. "New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers" Journal of Clinical Medicine 14, no. 3: 700.
https://doi.org/10.3390/jcm14030700
APA Style
Battaglia, G., Lazzarotto, D., Tanasi, I., Gurrieri, C., Forlani, L., Mauro, E., Capraro, F., Ciotti, G., De Bellis, E., Callegari, C., Tosoni, L., Fanin, M., Morelli, G. L., Simio, C., Skert, C., Gottardi, M., Zaja, F., Toffoletti, E., Damiani, D.,
... Tiribelli, M.
(2025). New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers. Journal of Clinical Medicine, 14(3), 700.
https://doi.org/10.3390/jcm14030700
